Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gil-Delgado

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Comparative Immunology, Microbiology and Infectious Diseases|January 1, 1986
From experimental to clinical attempts in immunorestoration with bestatin and zincG Mathé, I Blazsek, C Canon, et al.
Melanoma Research|August 10, 2002
Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapyR Mouawad, E-C Antoine, M Gil-Delgado, et al.
Oncology (Williston Park, N.Y.)|May 12, 2001
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancerD Khayat, M Gil-Delgado, E C Antoine, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1978
Leukemic (or stage V) lymphosarcomaG Mathé, J L Misset, M Gil-Delgado, et al.
Bulletin Du Cancer|February 5, 1999
[Irinotecan in combination for colon cancer]M Ducreux, M Gil-Delgado, T André, et al.
The British Journal of Dermatology|August 22, 2000
A comparative study of Fas and Fas-ligand expression during melanoma progressionC Soubrane, R Mouawad, E C Antoine, et al.
Melanoma Research|June 25, 1999
Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?R Mouawad, D Khayat, S Merle, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Retrospective study correlating clinical infectious history and peripheral blood T-cell subpopulations in cancer, GvH and HIV+ patientsG Mathé, P Meyer, S Brienza, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patientsG Mathé, J L Misset, M Gil-Delgado, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
European experience with irinotecan plus fluorouracil/folinic acid or mitomycinD Khayat, M Gil-Delgado, E C Antoine, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Comparative Immunology, Microbiology and Infectious Diseases|January 1, 1986
From experimental to clinical attempts in immunorestoration with bestatin and zincG Mathé, I Blazsek, C Canon, et al.
Melanoma Research|August 10, 2002
Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapyR Mouawad, E-C Antoine, M Gil-Delgado, et al.
Oncology (Williston Park, N.Y.)|May 12, 2001
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancerD Khayat, M Gil-Delgado, E C Antoine, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1978
Leukemic (or stage V) lymphosarcomaG Mathé, J L Misset, M Gil-Delgado, et al.
Bulletin Du Cancer|February 5, 1999
[Irinotecan in combination for colon cancer]M Ducreux, M Gil-Delgado, T André, et al.
The British Journal of Dermatology|August 22, 2000
A comparative study of Fas and Fas-ligand expression during melanoma progressionC Soubrane, R Mouawad, E C Antoine, et al.
Melanoma Research|June 25, 1999
Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?R Mouawad, D Khayat, S Merle, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Retrospective study correlating clinical infectious history and peripheral blood T-cell subpopulations in cancer, GvH and HIV+ patientsG Mathé, P Meyer, S Brienza, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
A phase II trial of immunorestoration with zinc gluconate in immunodepressed cancer patientsG Mathé, J L Misset, M Gil-Delgado, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
European experience with irinotecan plus fluorouracil/folinic acid or mitomycinD Khayat, M Gil-Delgado, E C Antoine, et al.
Pageof 2